Rangeley Capital, LLC Elevation Oncology, Inc. Transaction History
Rangeley Capital, LLC
- $83.8 Billion
- Q2 2025
A detailed history of Rangeley Capital, LLC transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Rangeley Capital, LLC holds 905,289 shares of ELEV stock, worth $325,904. This represents 0.4% of its overall portfolio holdings.
Number of Shares
905,289Holding current value
$325,904% of portfolio
0.4%Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
66Shares Held
32MCall Options Held
50KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.16 Million0.12% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$2.12 Million1.64% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.02 Million0.29% of portfolio
-
Black Rock Inc. New York, NY2.49MShares$896,4890.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.26MShares$812,4080.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.39M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...